triazoles has been researched along with Disease Exacerbation in 150 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (6.67) | 18.2507 |
| 2000's | 45 (30.00) | 29.6817 |
| 2010's | 89 (59.33) | 24.3611 |
| 2020's | 6 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asim, M; Ateeq, B; Bhatia, V; Biswas, T; Carskadon, S; Goel, S; Gupta, N; Kundu, S; Morrissey, C; Palanisamy, N | 1 |
| Benedyk-Machaczka, M; Blø, M; Chen, TJ; Furriol, J; Gausdal, G; Kalucka, U; Kamińska, M; Lorens, J; Marti, HP; Mydel, P; Osman, T | 1 |
| Aresté, C; Colell, A; Coll, M; Cristóbal, H; Cucarull, B; de Gregorio, E; García de Frutos, P; Gausdal, G; Graupera, I; Lorens, JB; Marí, M; Morales, A; Tutusaus, A | 1 |
| Farstad, IN; Flem-Karlsen, K; Flørenes, VA; Jacobsen, KD; McFadden, E; Mælandsmo, GM; Nyakas, M; Wernhoff, P | 1 |
| Díaz, ML; Echeverría, LE; Eduardo Nieto, J; González, CI; Hernandez, JCM; López-Romero, LA; Morillo, CA; Ochoa, SAG; Rivera, JD; Rojas, LZ; Suárez, EU | 1 |
| Bae, CA; Brekken, RA; Ham, IH; Han, SU; Hur, H; Kim, TM; Lee, D; Lorens, JB; Oh, HJ; Park, WS; Son, SY; Woo, J; Yoon, JH | 1 |
| Abd Eldaim, MA; Abdallah, AEM; Abdel-Daim, MM; Abdelaziz, SAM; Abdul Rashid, S; Abdullah, AS; Abdullah, LC; Abramson, MJ; Ahmed, HB; Ahmed, MM; Ahn, YC; Alexander, DC; Ando, T; Angelone, AM; Anglani, F; Ap, Y; Arthanari, SK; Axelrad, C; Bai, S; Bakonyi, P; Barnes, E; Beckmann, NA; Bélafi-Bakó, K; Bennett, CM; Bestha, RM; Bitsch, RG; Bradley, CA; Bu, Y; Calò, LA; Cañedo-Villaroya, E; Carlson, L; Caruso, S; Casado-Flores, J; Ceol, M; Cesarino, I; Chen, IL; Chen, R; Chen, X; Chilvers, MI; Cho, WK; Choong, TSY; Conceição-Neto, N; Culver, EL; Dai, X; de Lama Caro-Patón, G; De Rosa, I; Del Prete, D; Dharmage, SC; Dimitriadis, E; Dittakavi, S; Dobrowolski, JC; Edin, S; Elgarawany, GE; Emam, HE; Emmens, RW; Erbas, B; Erwich, JJHM; Farghali, M; Feng, L; Funston, RN; Gabler, NK; Gale, P; Ganesh, M; Gao, J; Gao, L; Gao, X; García-Salido, A; Gatto, R; Gautam, S; Ge, C; Ghogomu, SM; Gianesello, L; Gonçales, VR; Gooch, JL; Gooding, JJ; Gourley, GG; Gu, H; Gu, X; Gu, Z; Guerreri, M; Guillén, M; Hazzaa, SM; Heylen, E; Hicks, R; Hong, X; Hoshi, M; Hu, B; Hu, LX; Hu, R; Hu, S; Huang, J; Huang, K; Hubbard, WB; Hui, J; Hwang, NY; Iannacci, J; Ianus, A; Iglesias-Bouzas, MI; Ihara, I; Iwasaki, M; Jaeger, S; Kandel, YR; Karpińska, G; Kim, HK; Klopfenstein, TJ; Knorr, D; Koók, L; Kotb, S; Kruithof, S; Larsson, P; Laurence, C; Leng, J; Li, H; Li, J; Li, Q; Li, S; Li, X; Li, Z; Lian, J; Liang, JX; Liang, X; Lighaam, LC; Lin, CW; Lin, HC; Lin, J; Ling, A; Liu, J; Liu, P; Liu, YS; Ljuslinder, I; Lo, GH; Lodge, CJ; Löfgren-Burström, A; Lowe, AJ; Lu, M; Lu, N; Lucero-Prisno, DE; Luebbe, KM; Luo, X; Ma, Z; Maes, P; Makuch, M; Malekbala, MR; Mao, Z; Martínez-Romera, I; Marzo, G; Mathew, FM; Mattei, A; Matthijnssens, J; Mayumi, M; Morita, N; Mueller, DS; Mullangi, R; Mummolo, S; Murthi, P; Myte, R; Nabeshima, T; Nakamoto, K; Nehdi, IA; Nemestóthy, N; Niessen, HWM; Noh, JM; Nota, A; Nunes, D; Oh, D; Öhlund, D; Olsen, KM; Ono, H; Osawa, Y; Palmqvist, R; Palombo, M; Park, M; Patience, JF; Peng, Y; Perng, DS; Persano, A; Priante, G; Prince, SJ; Pulipati, S; Pyo, H; Qiu, X; Quan, J; Quaranta, F; Quinzi, V; Rademacher, CJ; Rajaraman, G; Rashid, U; Rauch, JC; Rector, A; Remmerswaal, EBM; Ren, R; Rispens, T; Rocha, GS; Saad, NM; Saito, K; Salamova, A; Sarfaraz, K; Satoshi, A; Schnellmann, RG; Scholpa, NE; Schonhoff, M; Schwartz, KJ; Schwarze, M; Schweer, WP; Seiichi, Y; Serrano-González, A; Severino, J; Shemesh, N; Shi, ZQ; Shike, DW; Shim, YM; Siciliano, PA; Siebenrock, KA; Silva, MKL; Smith, DL; Soltani, S; Song, YM; Spry, ML; Stalker, LA; Stokes, RS; Sullivan, PG; Sun, JM; Sun, S; Svanes, C; Syo, K; Tai, CM; Takashima, S; Tashita, C; Taurino, A; Ten Berge, IJM; Tenuta, AU; Teo, SH; Tilley, RD; Trivedi, RK; Umetsu, K; Unger, PA; van Bruggen, R; van Ham, SM; Van Ranst, M; Vanitha, J; Vekaria, HJ; Venier, M; Venkateshwaran, K; Venkert, A; Vermeulen, E; Wan, C; Wang, H; Wang, N; Wang, P; Wang, T; Wang, X; Wang, Y; Wise, KA; Wolbink, GJ; Wu, J; Wu, P; Wu, S; Wu, Y; Xia, Q; Xin, W; Xiong, Q; Xu, H; Xu, P; Xue, S; Yamamoto, Y; Yamashiro, T; Yan, F; Yan, H; Yan, S; Yan, Y; Yang, JM; Yang, L; Yang, P; Ye, W; Yeh, JH; Yinda, CK; Ying, GG; Ying, L; Yoon, HG; Yu, H; Zainuddin, M; Zakkula, A; Zeller, M; Zeng, Y; Zha, J; Zhang, F; Zhang, H; Zhang, M; Zhang, Q; Zhang, S; Zhang, T; Zhang, Z; Zhao, C; Zhao, J; Zhao, Y; Zhong, Q; Zhu, J; Zingmark, C; Zo, JI; Zou, Y | 1 |
| Ummarino, D | 1 |
| Beltran, H; Demichelis, F; Rickman, DS; Rubin, MA | 1 |
| Labetoulle, R; Paul, S; Roblin, X | 1 |
| Armstrong-James, DPH; Eades, CP; Jones, A; Kelleher, P; Periselneris, J; Shah, A; Simmonds, N | 1 |
| Chen, C; Fei, K; Guo, L; Ju, R; Li, J; Li, S; Ye, C; Zhang, D; Zhu, L | 1 |
| Akiyoshi, T; Kuwamura, T; Murakami, S; Ogasa, Y; Suematsu, F; Tanaka, H; Umeda, S | 1 |
| Ding, D; Huang, H; Jimenez, R; Jin, X; Ma, T; Wang, D; Wang, L; Wu, H; Yan, Y; Ye, Z | 1 |
| Cong, Q; Gao, T; Jiang, W; Sun, M; Wang, Y; Xu, C; Yao, L; Yu, Y | 1 |
| Fujino, N; Fujishima, F; Ichinose, M; Inoue, A; Itakura, K; Kyogoku, Y; Miyauchi, E; Okada, Y; Okazaki, T; Okutomo, K; Saito, R; Sugiura, H; Tsukita, Y; Yamada, M | 1 |
| Duan, Q; Huang, T; Peng, Y; Wang, X; Xia, F; Yang, T; Zhang, W; Zhou, Y | 1 |
| Cheng, Z; Gong, Y; Knapp, S; Lu, K; Lu, X; Ma, Y; Muller, S; Pierce, LA; Thompson, RC; Wang, J | 1 |
| Cusick, T; Fisher, JE; Glantschnig, H; Kimmel, DB; Langdon, RB; Li, Z; Mu, J; Pennypacker, BL; Scott, KR; Shen, X; Zhang, BB | 1 |
| Camidge, DR; Ching, KA; Christensen, JG; Clark, JW; Diamond, JR; Eckhardt, SG; Kanteti, R; Lira, ME; LoRusso, PM; Salgia, R; Schoenmakers, EF; Varella-Garcia, M; Wilner, K; Xu, LG | 1 |
| Azzam, R; Katirji, B; Serra, A; Shaikh, AG | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Alumkal, J; Bottomly, D; Coleman, I; Gao, L; Gibbs, A; Kleinschmidt, R; Lisac, R; McWeeney, S; Nelson, P; Schwartzman, J; Wilmot, B | 1 |
| Cao, W; Li, F; Liu, X; Ma, Z; Qu, H; Wang, H; Wang, Y | 1 |
| Hamilton, J; Kamiya-Matsuoka, C; Kumar, VA; Kurzrock, R; Langford, LA; Moulder, S; Munoz, J; Pasche, LJ; Taggart, MW; Tummala, S | 1 |
| Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E | 1 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| D'Andrea, F; Grella, E; La Padula, S; Nicoletti, GF; Romanucci, V | 1 |
| Bencivelli, D; Borea, PA; Casetta, I; Corciulo, C; Gentile, M; Granieri, E; Varani, K; Vincenzi, F | 1 |
| Açıkgöz, ZC; Cağıl, N; Can, ME; Celikbilek, N; Dereli Can, G; Kalkan Akçay, E | 1 |
| Fox, DA; Gladue, HS | 1 |
| Costantino, F; Di Biasi, C; di Coste, A; Duse, M; Ernesti, I; Melengu, T; Savastano, V; Schiavi, L; Tarani, L | 1 |
| Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
| Guan, M; He, F; Li, C; Li, J; Wang, L; Xu, W; Xue, Y; Zeng, Y; Zheng, Z | 1 |
| Carpi, A; Ferrari, P; Nicolini, A; Rossi, G | 1 |
| Tohyama, K | 1 |
| Finkelstein, DM; Schoenfeld, DA | 2 |
| Panos, G; Watson, DC | 1 |
| Fan, Y; Gong, DD; Man, CF; Xu, J | 1 |
| Craig, AW; Everingham, S; Kapur, R; Sharma, N; Zeng, LF; Zhang, ZY | 1 |
| Cheng, JC; Chiu, KC; Chou, YT; Huang, RY; Lee, CH; Liu, SY; Shieh, YS; Yeh, CT; Yuh, DY | 1 |
| Brun-Vézinet, F; Charpentier, C; Damond, F; Descamps, D; Fagard, C; Glohi, D; Matheron, S; Rouard, C; Tubiana, R; Visseaux, B | 1 |
| Diamant, Z; Hanania, NA; Parulekar, AD | 1 |
| Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M | 1 |
| Albini, M; Casciato, S; Di Bonaventura, C; Fanella, M; Fattouch, J; Giallonardo, AT; Lapenta, L; Manfredi, M; Morano, A | 1 |
| Rich, P | 1 |
| Bagchi, MK; Chen, Y; Gong, P; Katzenellenbogen, BS; Katzenellenbogen, JA; Ko, C; Korach, KS; Nettles, KW; Nwachukwu, JC; Srinivasan, S; Taylor, RN; Zhao, Y | 1 |
| Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND | 1 |
| Bates, RC; Chu, J; Huang, Q; Inoue, T; Liu, Y; Rao, PE; Shin Ogawa, L; Sonderfan, AJ; Ye, J; Ying, W; Zhou, D | 1 |
| Bhathal, P; Doyle, A; Rusli, F | 1 |
| Shah, M; Shahani, L; Tavakoli-Tabasi, S | 1 |
| Buist, MR; Kenter, GG; van der Velden, J; van Driel, WJ; van Lonkhuijzen, LR; van Meurs, HS | 1 |
| Chen, J; Li, L; Qin, C; Ren, Y; Wan, Y; Wang, J; Wang, W; Wei, Q; Xu, J; Zhang, X | 1 |
| Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A | 1 |
| Kim, JS; Kim, MJ; Lim, W; Nam, JS; Park, SA; Park, SY; Yhong Sheen, Y | 1 |
| Sha, H; Sun, Y; Wei, S | 1 |
| Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Booth, CM; Eisenhauer, EA; Goodwin, RA; Goss, PE; Jamal, R; Shepherd, LE; Tu, D | 1 |
| Bradner, JE; Cluse, LA; Gregory, GP; Hogg, SJ; Johnstone, RW; Lefebure, M; Martin, BP; Newbold, A; Shortt, J; Tothill, RW; Vervoort, SJ; Vidacs, E | 1 |
| Abdul Razak, AR; Baker, S; Carlson, R; Condy, M; D'Angelo, SP; Dickson, MA; Ellis, J; Erinjeri, JP; Friedlander, S; Gounder, MM; Gupta, AA; Jasmine, FH; Kauffman, M; Keohan, ML; Loong, HH; Nyquist-Schultz, K; Rashal, T; Saint-Martin, JR; Salah, S; Schwartz, GK; Shacham, S; Tanner, L; Tap, WD; Unger, TJ; Zer, A | 1 |
| Aoki, T; Fujiwara, H; Fukayama, M; Hasegawa, K; Hoshikawa, M; Ijichi, H; Isayama, H; Koike, K; Kokudo, N; Kudo, Y; Miyabayashi, K; Morishita, Y; Nakai, Y; Nakatsuka, T; Sakamoto, Y; Takahashi, R; Tanaka, M; Tanaka, Y; Tateishi, K; Yamamoto, K | 1 |
| Allegrezza, MJ; Bengsch, F; Bitler, BG; Bradner, JE; Conejo-Garcia, JR; Kossenkov, AV; Rutkowski, MR; Svoronos, N; Yokoyama, Y; Zhang, R; Zhu, H | 1 |
| Kanaho, Y; Miura, Y; Yamauchi, Y | 1 |
| Burki, TK | 1 |
| Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE | 1 |
| Bodurka, DC; Coleman, RL; Gershenson, DM; Lu, KH; Malpica, A; Sun, CC | 1 |
| Kurmann, PT; Nemitz, N; Van Linthoudt, D | 1 |
| Bohrer, J; Chen, CC; Falcone, T | 1 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| Ejlertsen, B; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB | 1 |
| Hamamura, R; Kobayashi, C; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Barker, LC; Brand, IR; Crawford, SM | 1 |
| Bourcier, T; Fabre, M; Labetoulle, M; Offret, H; Proença-Pina, J; Ssi Yan Kai, I | 1 |
| Albarrag, A; Anderson, MJ; Arendrup, MC; Cerar, D; Denning, DW; Fisher, MC; Howard, SJ; Laverdiere, M; Pasqualotto, AC; Perlin, DS | 1 |
| Ballerini, P; Biagioni, F; Buccella, S; Caciagli, F; Ciccarelli, R; Citraro, R; D'Alimonte, I; D'Auro, M; De Sarro, G; Di Iorio, P; Giuliani, P; Jiang, S; Nargi, E; Russo, E | 1 |
| Bode, BW | 1 |
| Agostinho, PM; Cognato, GP; Cunha, RA; Hockemeyer, J; Müller, CE; Souza, DO | 1 |
| Albaladejo, CV; Almenar, S; Calatrava, A; Campos, J; Cervera-Deval, J; Climent, MA; Fernandez-Serra, A; Garcia-Casado, Z; Gavila, J; Guerrero-Zotano, A; Guillem, V; Llombart-Bosch, A; Llombart-Cussac, A; Lopez-Guerrero, JA; Ruiz-Simon, A | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
| Cefalu, WT | 1 |
| Jung, SY; Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J | 1 |
| Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D | 1 |
| Fisher, C; Jones, RL; Judson, IR; Ratnayake, G; Scurr, M; Thway, K | 1 |
| Danna, R; Herbrecht, R; Papadopoulos, G; Rajagopalan, S | 1 |
| Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y | 1 |
| Aihara, Y; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Shirai, Y; Tsujimoto, T; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Bunck, M; Gaburro, S; Hauschild, M; Landgraf, R; Sartori, SB; Singewald, N | 1 |
| Hong, SH; Jeong, J; Kim, SY; Lee, H; Lee, KS; Lee, YS; Nam, BH; Park, IH; Ro, J | 1 |
| Bhagwat, K; Brooks, M; Eisen, D; Royse, A; Royse, C; Sparks, P | 1 |
| Blatt, K; Bradner, JE; Brown, P; Chicas, A; Herrmann, H; Johns, C; Kogan, SC; Lowe, SW; Magoon, D; Mulloy, JC; Qi, J; Rappaport, AR; Shi, J; Sison, EA; Taylor, MJ; Vakoc, CR; Valent, P; Wang, E; Wunderlich, M; Zuber, J | 1 |
| DiBartolo, MA; Kelley, PS | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Correa, PD; Han, S; Rizwanullah, M; Shrimali, RK | 1 |
| Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Mewar, D; Michael, B; Tunn, E; Williams, S | 1 |
| Alvarez-Ríos, AI; Ferrando-Martinez, S; García-García, M; Genebat, M; Gonzalez-Serna, A; Leal, M; Machmach, K; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E | 1 |
| Brokalaki, EI; Hillen, U; Sommerwerck, U; von Heinegg, EH | 1 |
| Bulun, SE; Chai, D; Fazleabas, A; Gurates, B; Langoi, D; Pavone, ME | 1 |
| Allen, PB; Baer, MR; Kleinberg, ME; Koka, R | 1 |
| Glück, S; Untch, M; von Minckwitz, G | 1 |
| Bakris, GL; Flynn, C | 1 |
| Bowman, A; Gabra, H; Langdon, SP; Lessells, A; Smyth, JF; Stewart, M; Young, A | 1 |
| Vergote, I | 1 |
| Howell, A | 1 |
| Gluck, S | 1 |
| Stasi, R; Terzoli, E | 1 |
| Thornton, H | 1 |
| Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T | 1 |
| Campos, SM; Winer, EP | 1 |
| Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I | 1 |
| Buzdar, A; Come, SE; Ellis, M; Gertler, S; Howell, A; Jones, SE; Kleeberg, UR; Mauriac, L; Morris, C; Osborne, CK; Robertson, JF; Vergote, I; Webster, A | 1 |
| Baboor, M; Diaz, MC; Fica, A; Luppi, M; Olivares, R; Saez, L; Vasquez, P | 1 |
| Cheung, KL; Forward, DP; Jackson, L; Robertson, JF | 1 |
| Ellis, MJ | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A | 1 |
| Barchiesi, F; Carle, F; Giannini, D; Maracci, M; Scalise, G; Schimizzi, AM; Spreghini, E | 1 |
| Chaudri-Ross, HA; Mouridsen, H | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L | 1 |
| Ansari, TN; Hussain, I; Mahmood, A; Samad, A | 1 |
| Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, D; Hackl, W; Hamer, P; Harvey, HA; Lang, R; Leitzel, K; Lipton, A | 1 |
| Bertelli, G; Bertolotti, L; Carlini, P; Conforti, S; Del Mastro, L; Febbraro, A; Garrone, O; Leonard, RC; Liossi, C; Marzano, N; Occelli, M | 1 |
| Dutcher, JP; Friedland, DM; Leon, L; Manola, J; Roth, B; Wilding, G | 1 |
| Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F | 1 |
| Al-Attar, A; Redett, RJ; Williams, CG | 1 |
| Ambrose, PG; Andes, D; Bhavnani, SM; Knasinski, V; Safdar, N; Simmons, W; Smith, J | 1 |
| Alba, E; Barnadas, A; Carabante, F; Colomer, R; Fernández, R; Gil, M; González, J; Llombart, A; Mayordomo, JI; Palomero, I; Ramos, M; Ribelles, N; Ruiz, M; Soriano, V; Tusquets, I; Vera, R | 1 |
| Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC | 1 |
| Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I | 1 |
| Mouridsen, HT | 1 |
| Drago, V; Foster, P; Heilman, KM; Schmalfuss, IM; Skidmore, FM; Streiff, RR | 1 |
| Blanchett, D; Bondarenko, IN; Goss, P; Langecker, P; Manikhas, GN; Miller, WH; Pendergrass, KB | 1 |
| Cameron, D; Dixon, JM; Evans, DB; Kerr, GR; Macaskill, EJ; Miller, WR; Murray, J; Renshaw, L; Young, O | 1 |
| Coleman, RL; Deavers, M; Gershenson, DM; Kavanagh, JJ; Levenback, C; Milam, MR; Ramirez, PT; Schmeler, KM; Slomovitz, BM; Smith, JA | 1 |
| Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM | 1 |
| Azab, M; Blomqvist, C; Eiermann, W; Hellmund, R; Howell, A; Jonat, W; Lundgren, S; Mauriac, L; Roche, H; Tyrrell, C; Winblad, G | 1 |
| Bellmunt, J; Bezwoda, W; Chaudri, HA; Dombernowsky, P; Falkson, G; Fornasiero, A; Gardin, G; Gudgeon, A; Hatschek, T; Hoffmann, W; Hornberger, U; Leonard, R; Michel, J; Morgan, M; Panasci, L; Smith, I; Tjabbes, T; Trunet, PF | 1 |
| Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G | 1 |
| Blomqvist, CP; Buzdar, AU; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Lee, D; Steinberg, M; Vogel, CL; Webster, A; Wolter, JM | 1 |
| Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA | 1 |
| Bruynseels, J; De Coster, R; Goss, PE; Langenaeken, C; Walde, D | 1 |
| Hamilton, A; Piccart, M | 1 |
| Goss, PE; Schwartz, LH; Tannock, IF; Winer, EP | 1 |
| Coombes, RC; Harper-Wynne, C | 1 |
| Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B | 1 |
| Cocconi, G | 1 |
| Carlini, P; Casali, A; Cognetti, F; De Marco, S; Fabi, A; Frassoldati, A; Nardi, M; Paoloni, F; Papaldo, P; Ruggeri, EM | 1 |
24 review(s) available for triazoles and Disease Exacerbation
| Article | Year |
|---|---|
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Heart failure: BRD4 inhibition slows HF progression.
Topics: Animals; Azepines; Cell Cycle Proteins; Disease Progression; Heart Failure; Humans; Nuclear Proteins; Transcription Factors; Triazoles | 2017 |
Filgotinib for the treatment of Crohn's disease.
Topics: Crohn Disease; Disease Progression; Gastrointestinal Agents; Humans; Janus Kinase Inhibitors; Pyridines; Severity of Illness Index; Triazoles; Tumor Necrosis Factor-alpha | 2018 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Rhinocerebral zygomycosis with pansinusitis in a 14-year-old girl with type 1 diabetes: a case report and review of the literature.
Topics: Adolescent; Antifungal Agents; Blindness; Diabetes Mellitus, Type 1; Disease Progression; Electromyography; Female; Follow-Up Studies; Fungemia; Humans; Immunocompromised Host; Magnetic Resonance Imaging; Meningitis, Fungal; Nose Diseases; Opportunistic Infections; Rare Diseases; Risk Assessment; Severity of Illness Index; Treatment Outcome; Triazoles; Zygomycosis | 2013 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Topics: CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Disease Progression; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Receptors, CCR5; Receptors, CXCR4; Triazoles; Viral Tropism; Virus Internalization | 2015 |
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles; Women | 2014 |
Antifungals in severe asthma.
Topics: Adrenal Cortex Hormones; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigatus; Asthma; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Severity of Illness Index; Treatment Outcome; Triazoles | 2015 |
Effectiveness of Rufinamide in the Treatment of Idiopathic Generalized Epilepsy With Atypical Evolution: Case Report and Review of the Literature.
Topics: Adult; Anticonvulsants; Disease Progression; Electroencephalography; Epilepsy, Absence; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Female; Humans; Treatment Outcome; Triazoles | 2016 |
Aceruloplasminaemia: a rare but important cause of iron overload.
Topics: Adult; Benzoates; Ceruloplasmin; Chelation Therapy; Deferasirox; Disease Progression; Early Diagnosis; Ferritins; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Treatment Outcome; Triazoles | 2015 |
Immune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.
Topics: CCR5 Receptor Antagonists; CD8-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; JC Virus; Leukoencephalopathy, Progressive Multifocal; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles | 2015 |
Machineries regulating the activity of the small GTPase Arf6 in cancer cells are potential targets for developing innovative anti-cancer drugs.
Topics: Adaptor Proteins, Signal Transducing; ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Animals; Antineoplastic Agents; Cell Cycle Proteins; Chlorobenzenes; Disease Progression; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Nerve Tissue Proteins; Purines; Pyrazoles; Pyrimidinones; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Triazoles | 2017 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles | 2009 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles | 2012 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease Management; Disease Progression; Drug Therapy, Combination; Female; Geriatric Assessment; Health Status; Humans; Letrozole; Life Expectancy; Nitriles; Prognosis; Quality of Life; Treatment Outcome; Triazoles | 2013 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Hormonal therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Gonadotropin-Releasing Hormone; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Progestins; Triazoles | 2003 |
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Gene Expression Profiling; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
31 trial(s) available for triazoles and Disease Exacerbation
| Article | Year |
|---|---|
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Therapy, Combination; Female; Goserelin; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Pregnancy; Survival Analysis; Treatment Outcome; Triazoles; Young Adult | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early.
Topics: Administration, Topical; Adult; Antifungal Agents; Disease Progression; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prospective Studies; Time Factors; Treatment Outcome; Triazoles | 2015 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Male; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Benzylamines; Biopsy; Blood Glucose; Blood Transfusion; Cholesterol, LDL; Combined Modality Therapy; Cyclams; Diabetes Mellitus, Type 2; Disease Progression; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Glycated Hemoglobin; Granulocyte Colony-Stimulating Factor; Hamstring Muscles; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Hydrazines; Immunohistochemistry; Insulin-Secreting Cells; Leg; Male; Middle Aged; Muscle Strength; Neoplasms; Peripheral Blood Stem Cell Transplantation; Range of Motion, Articular; Recurrence; Remission Induction; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Soccer; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Triazoles; Young Adult | 2015 |
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Capsules; Disease Progression; Drug Administration Schedule; Drug Compounding; Fasting; Female; Food-Drug Interactions; Humans; Hydrazines; Male; Middle Aged; New York City; Pharmaceutical Solutions; Postprandial Period; Sarcoma; Soft Tissue Neoplasms; Tablets; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triazoles; Young Adult | 2016 |
Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Density; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Goserelin; Humans; Immunohistochemistry; Injections, Subcutaneous; Kaplan-Meier Estimate; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Triazoles | 2010 |
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Disease Progression; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2011 |
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; CA-125 Antigen; Disease Progression; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2002 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2002 |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Estradiol; Estrone; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate; Triazoles | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Treatment Outcome; Triazoles | 2003 |
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Female; Goserelin; Humans; Injections, Subcutaneous; Middle Aged; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Prognosis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Topics: Administration, Oral; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Triazoles | 2005 |
Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Patient Selection; Time Factors; Treatment Outcome; Triazoles | 2005 |
Letrozole in advanced breast cancer: the PO25 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Cross-Over Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Quality of Life; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Topics: Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Steroid; Toremifene; Triazoles | 2007 |
Increase in response rate by prolonged treatment with neoadjuvant letrozole.
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Humans; Letrozole; Life Expectancy; Mastectomy; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2009 |
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Taxoids; Treatment Outcome; Triazoles | 2008 |
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles | 1996 |
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Megestrol; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Quality of Life; Remission Induction; Survival Rate; Triazoles | 1996 |
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Survival Rate; Triazoles | 1998 |
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Topics: Administration, Oral; Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Prognosis; Survival Rate; Treatment Failure; Triazoles | 1998 |
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Megestrol; Nitriles; Postmenopause; Proportional Hazards Models; Survival Rate; Triazoles | 1998 |
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 1995 |
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Triazoles | 1999 |
Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Topics: Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Nitriles; Postmenopause; Prospective Studies; Receptors, Estrogen; Treatment Outcome; Triazoles | 1999 |
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; ErbB Receptors; Estrogen Antagonists; Female; Humans; Letrozole; Logistic Models; Neoadjuvant Therapy; Nitriles; Odds Ratio; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Prostaglandin; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
96 other study(ies) available for triazoles and Disease Exacerbation
| Article | Year |
|---|---|
Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
Topics: Androgen Antagonists; Animals; Azepines; Cell Line, Tumor; Disease Progression; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Homeodomain Proteins; Humans; Male; Mice; Mice, Knockout; Mice, SCID; Neoplasm Metastasis; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Serine Endopeptidases; Signal Transduction; Survival Analysis; Transcription Factors; Transcription, Genetic; Transcriptional Regulator ERG; Triazoles; Xenograft Model Antitumor Assays | 2021 |
AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
Topics: Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Humans; Kidney Neoplasms; Mice; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Signal Transduction; Triazoles | 2021 |
A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Topics: Adult; Aged; Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Biomarkers; Biopsy; c-Mer Tyrosine Kinase; Cells, Cultured; Disease Models, Animal; Disease Progression; Female; Hepatic Stellate Cells; Hepatocytes; Humans; Intercellular Signaling Peptides and Proteins; Kupffer Cells; Liver; Liver Cirrhosis; Male; Mice; Mice, Knockout; Middle Aged; Non-alcoholic Fatty Liver Disease; Primary Cell Culture; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor; Triazoles | 2020 |
Soluble AXL as a marker of disease progression and survival in melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Biomarkers, Tumor; Cell Line, Tumor; Disease Progression; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Staging; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Skin Neoplasms; Solubility; Survival Rate; Triazoles | 2020 |
Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas.
Topics: Acute Disease; Animals; Chagas Disease; Disease Models, Animal; Disease Progression; DNA, Protozoan; Drug Therapy, Combination; Nitroimidazoles; Parasite Load; Parasitemia; Rats; Rats, Wistar; Triazoles; Trypanocidal Agents | 2020 |
Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma.
Topics: Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Phosphorylation; Prognosis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Survival Rate; Triazoles; Tumor Cells, Cultured | 2020 |
Biology and evolution of poorly differentiated neuroendocrine tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azepines; Benzodiazepines; Carcinogenesis; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cell Differentiation; Cell Lineage; Cell Plasticity; Colonic Neoplasms; Disease Progression; Epigenesis, Genetic; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Neuroendocrine Tumors; Ovarian Neoplasms; Prostatic Neoplasms; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyrimidines; Retinoblastoma Binding Proteins; Triazoles; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2017 |
Improvement in Exophiala dermatitidis airway persistence and respiratory decline in response to interferon-gamma therapy in a patient with cystic fibrosis.
Topics: Amphotericin B; Antifungal Agents; Cystic Fibrosis; Disease Progression; Exophiala; Humans; Interferon-gamma; Interleukin-17; Lung Diseases, Fungal; Male; Monitoring, Immunologic; Nitriles; Pyridines; Recombinant Proteins; Respiratory Function Tests; Sputum; Treatment Outcome; Triazoles; Young Adult | 2018 |
Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Deoxyglucose; Disease Progression; Drug Interactions; Female; Glycolysis; Humans; Intracellular Space; Mice; Mice, Inbred BALB C; Mitochondria; Pancreatic Neoplasms; Triazoles; Xenograft Model Antitumor Assays | 2018 |
[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Humans; Middle Aged; Nitriles; Patient Compliance; Retrospective Studies; Triazoles | 2018 |
DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Drug Resistance, Neoplasm; Endopeptidases; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Male; Mice; Nuclear Proteins; Nuclear Receptor Co-Repressor 2; Piperazines; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proteolysis; Pyridines; Signal Transduction; Transcription Factors; Transcription, Genetic; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor.
Topics: Animals; Azepines; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Disease Progression; Female; Humans; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Platelet Activating Factor; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Triazoles; Tumor Microenvironment | 2018 |
Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; B7-H1 Antigen; Benzocycloheptenes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cohort Studies; Disease Progression; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, CXCR6; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Triazoles | 2019 |
Bromodomain-containing protein 4 contributes to renal fibrosis through the induction of epithelial-mesenchymal transition.
Topics: Animals; Azepines; Case-Control Studies; Cell Cycle Proteins; Cells, Cultured; Disease Models, Animal; Disease Progression; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Hypertension, Renal; Kidney; Male; Mice; Mice, Inbred C57BL; Nephritis; Nuclear Proteins; Transcription Factors; Triazoles | 2019 |
Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Topics: Animals; Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Mice; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; RNA Interference; Signal Transduction; Transcription, Genetic; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione.
Topics: Absorptiometry, Photon; Animals; Bone Density; Disease Progression; Estrogens; Female; Femur; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Ovariectomy; Pyrazines; Rats; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Heterozygote; Humans; In Situ Hybridization, Fluorescence; Kidney Neoplasms; Male; Methionine; Middle Aged; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazines; Receptor Protein-Tyrosine Kinases; Sequence Analysis, DNA; Threonine; Treatment Failure; Triazoles | 2013 |
Exacerbation of myasthenia gravis with voriconazole.
Topics: Antifungal Agents; Aspergillosis; Blepharoptosis; Computer Simulation; Disease Progression; Female; Humans; Middle Aged; Myasthenia Gravis; Ophthalmoplegia; Pyrimidines; Triazoles; Voriconazole | 2013 |
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
Topics: Androgens; Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-myc; Receptors, Androgen; Triazoles; Up-Regulation | 2013 |
Posterior reversible encephalopathy syndrome: more than meets the eye.
Topics: Anastrozole; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Electroencephalography; Fatal Outcome; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Multiple Primary; Nitriles; Posterior Leukoencephalopathy Syndrome; Risk Assessment; Triazoles | 2013 |
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles | 2014 |
Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: clinical and surgical management.
Topics: Anastrozole; Aromatase Inhibitors; Breast; Child; Combined Modality Therapy; Disease Progression; Diseases in Twins; Gynecomastia; Humans; Male; Mastectomy; Nitriles; Organ Size; Peutz-Jeghers Syndrome; Testis; Triazoles; Twins, Monozygotic | 2013 |
A(2A) adenosine receptors and Parkinson's disease severity.
Topics: Adenosine A2 Receptor Agonists; Aged; Disease Progression; Dose-Response Relationship, Drug; Dyskinesias; Female; Humans; Lymphocytes; Male; Middle Aged; Parkinson Disease; Protein Binding; Receptor, Adenosine A2A; Statistics, Nonparametric; Triazines; Triazoles; Tritium | 2014 |
[Fungal keratitis caused by Scedosporium apiospermum: first report from Turkey].
Topics: Antifungal Agents; Conjunctiva; Cornea; Disease Progression; Drug Resistance, Fungal; Drug Therapy, Combination; Eye Foreign Bodies; Eye Infections, Fungal; Eye Injuries; Female; Humans; Keratitis; Keratoplasty, Penetrating; Middle Aged; Natamycin; Pyrimidines; Scedosporium; Treatment Refusal; Triazoles; Turkey; Voriconazole | 2013 |
Voriconazole-induced periostitis causing arthralgias mimicking a flare of granulomatosis with polyangiitis.
Topics: Aged; Alkaline Phosphatase; Antifungal Agents; Arthralgia; Diagnosis, Differential; Disease Progression; Female; Granulomatosis with Polyangiitis; Hip Joint; Humans; Periostitis; Pulmonary Aspergillosis; Pyrimidines; Triazoles; Voriconazole | 2013 |
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pyrazines; Random Allocation; Sitagliptin Phosphate; Triazoles | 2014 |
Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Immunity, Cellular; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Middle Aged; Mucin-1; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Proportional Hazards Models; Selective Estrogen Receptor Modulators; T-Lymphocytes; Tamoxifen; Tissue Polypeptide Antigen; Toremifene; Triazoles | 2014 |
A joint test for progression and survival with interval-censored data from a cancer clinical trial.
Topics: Antineoplastic Agents; Bias; Breast Neoplasms; Clinical Trials as Topic; Data Interpretation, Statistical; Disease Progression; Disease-Free Survival; Female; Humans; Letrozole; Models, Statistical; Nitriles; Triazoles | 2014 |
Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dasatinib; Disease Progression; Drug Synergism; Humans; Indoles; Mastocytosis, Systemic; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-kit; Signal Transduction; Triazoles | 2014 |
Protumoral effect of macrophage through Axl activation on mucoepidermoid carcinoma.
Topics: Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Carcinoma, Mucoepidermoid; Cell Culture Techniques; Cell Line; Cell Line, Tumor; Cell Movement; Coculture Techniques; Disease Progression; Enzyme Activation; Humans; Macrophage Activation; Macrophages; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Triazoles | 2014 |
HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
Topics: CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Disease Progression; Drug Resistance, Viral; Genotype; HIV Infections; HIV-2; Humans; Maraviroc; Prevalence; Receptors, CCR5; Retrospective Studies; Triazoles; Viral Load; Viral Tropism | 2014 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Everolimus; Female; Humans; Kazakhstan; Letrozole; Nitriles; Postmenopause; Receptor, ErbB-2; Triazoles | 2015 |
Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis.
Topics: Animals; Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Embryonic Stem Cells; Endometriosis; Estrogens; Female; Fertility; Humans; Indazoles; Inflammation; Letrozole; Ligands; Macrophages; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Nitriles; Receptors, Estrogen; Stromal Cells; Treatment Outcome; Triazoles | 2015 |
The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.
Topics: Animals; B-Lymphocytes; Cyclophosphamide; Cytokines; Disease Models, Animal; Disease Progression; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Spleen; T-Lymphocytes; Triazoles | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Goserelin; Granulosa Cell Tumor; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Ovarian Neoplasms; Ovariectomy; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salpingectomy; Tamoxifen; Triazoles | 2015 |
Mucosal Topical Microbicide Candidates Exert Influence on the Subsequent SIV Infection and Survival by Regulating SIV-Specific T-Cell Immune Responses.
Topics: Administration, Rectal; Animals; Anti-Infective Agents, Local; CD4-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; Gene Expression Profiling; Humans; Immunity, Cellular; Macaca mulatta; Maraviroc; Mucous Membrane; Oligonucleotide Array Sequence Analysis; Peptides; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Survival Rate; Tenofovir; Triazoles; Viral Load | 2016 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Diarrhea; Disease Progression; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Retrospective Studies; Survival Rate; Triazoles | 2015 |
TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Communication; Cell Line, Transformed; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Epithelial-Mesenchymal Transition; Female; Focal Adhesion Protein-Tyrosine Kinases; Hepatic Stellate Cells; Heterografts; Humans; Liver Neoplasms; Mice; Proto-Oncogene Proteins c-akt; Signal Transduction; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Triazoles | 2015 |
Therapeutic targeting of BET protein BRD4 delays murine lupus.
Topics: Animals; Azepines; Disease Progression; DNA; Humans; Kidney; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred MRL lpr; Monocytes; Nerve Tissue Proteins; Nuclear Proteins; Proteinuria; Receptors, Cell Surface; Spleen; Tetrazolium Salts; Thiazoles; Transcription Factors; Triazoles | 2015 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles | 2016 |
Assessing survival benefit when treatment delays disease progression.
Topics: Aromatase Inhibitors; Bayes Theorem; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Neoplasm Staging; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Rate; Triazoles | 2016 |
Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Disease-Free Survival; Female; Humans; Hypertension; Letrozole; Lymphatic Metastasis; Middle Aged; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2016 |
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Topics: Animals; Apoptosis; Azepines; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Lymphoma, B-Cell; Mice; Multigene Family; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); Signal Transduction; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Topics: Actins; Animals; Azepines; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Cytokines; Disease Progression; Epigenesis, Genetic; Hedgehog Proteins; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pancreas; Pancreatic Neoplasms; Primary Cell Culture; Proteins; Signal Transduction; STAT3 Transcription Factor; Transcription, Genetic; Transforming Growth Factor beta; Triazoles; Xenograft Model Antitumor Assays | 2016 |
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Topics: Animals; Azepines; B7-H1 Antigen; Cell Cycle Proteins; Cell Line, Tumor; Disease Progression; Female; Humans; Immunity; Mice, Inbred C57BL; Neoplasms; Nuclear Proteins; Proteins; T-Lymphocytes, Cytotoxic; Time Factors; Transcription Factors; Transcription, Genetic; Triazoles | 2016 |
Palbociclib improves survival in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2017 |
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Leuprolide; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Survival Rate; Tamoxifen; Triazoles; Watchful Waiting; Young Adult | 2017 |
[Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Female; Fibromyalgia; Humans; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2008 |
Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor.
Topics: Anastrozole; Aromatase Inhibitors; Disease Progression; Endometriosis; Female; Humans; Kidney Function Tests; Middle Aged; Nitriles; Severity of Illness Index; Stents; Treatment Failure; Triazoles; Ureteral Diseases; Ureteral Obstruction; Urologic Surgical Procedures | 2008 |
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Immunohistochemistry; Letrozole; Microarray Analysis; Middle Aged; Nitriles; Patient Selection; Pilot Projects; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Topics: Animals; Apoptosis; Benzoates; Cell Line, Tumor; Deferasirox; Disease Progression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Iron Chelating Agents; Leukemia, Myeloid; Mice; Mice, Nude; Protein Kinases; Ribosomal Protein S6; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2009 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Organ Size; Retrospective Studies; Time Factors; Triazoles | 2009 |
Fusarium keratitis and endophthalmitis associated with lens contact wear.
Topics: Adult; Antifungal Agents; Contact Lens Solutions; Contact Lenses; Cornea; Corneal Transplantation; Disease Progression; Drug Resistance, Fungal; Endophthalmitis; Fusarium; Humans; Keratitis; Male; Patient Compliance; Pyrimidines; Time Factors; Triazoles; Visual Acuity; Voriconazole | 2010 |
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.
Topics: Amino Acid Substitution; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Azoles; Cytochrome P-450 Enzyme System; Disease Progression; Drug Resistance, Fungal; Evolution, Molecular; Fungal Proteins; Humans; Itraconazole; Pyrimidines; Treatment Failure; Triazoles; Voriconazole | 2009 |
Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease.
Topics: Adenosine; Age Factors; Analysis of Variance; Animals; Blotting, Western; Disease Models, Animal; Disease Progression; Electroencephalography; Epilepsy, Absence; Glutamic Acid; Immunohistochemistry; Male; MAP Kinase Signaling System; Microinjections; Phenethylamines; Pyrimidines; Rats; Receptor, Adenosine A2A; Somatosensory Cortex; Thalamus; Triazoles | 2009 |
Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Animals, Newborn; Caffeine; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Glial Fibrillary Acidic Protein; Kainic Acid; Memory Disorders; Neurotoxicity Syndromes; Phosphodiesterase Inhibitors; Purines; Pyrimidines; Qa-SNARE Proteins; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Seizures; Synapses; Synaptophysin; Synaptosomal-Associated Protein 25; Triazoles; Tritium; Xanthines | 2010 |
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
Topics: 3' Untranslated Regions; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase; Breast Neoplasms; Disease Progression; Female; Humans; Immunohistochemistry; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Polymorphism, Genetic; Postmenopause; Treatment Outcome; Triazoles | 2010 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Fungal spinal cord compression in metastatic synovial sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Fractures, Spontaneous; Humans; Lung Neoplasms; Mycoses; Neoplasm Recurrence, Local; Neoplasm Staging; Osteomyelitis; Pneumonectomy; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma, Synovial; Spinal Cord Compression; Spinal Cord Neoplasms; Triazoles; Voriconazole | 2011 |
Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
Topics: Algorithms; Antifungal Agents; Aspergillosis; Cause of Death; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Resistance, Fungal; Humans; Matched-Pair Analysis; Survival Analysis; Triazoles; United States | 2010 |
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzoates; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Choline Deficiency; Deferasirox; Disease Progression; Drug Therapy, Combination; Fatty Liver; Hepatic Stellate Cells; Iron Chelating Agents; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Rats, Inbred F344; Time Factors; Transforming Growth Factor beta1; Triazoles | 2011 |
Enhanced fear expression in a psychopathological mouse model of trait anxiety: pharmacological interventions.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Behavior, Animal; Corticosterone; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Expressed Emotion; Fear; Fluorobenzenes; Male; Mice; Neurokinin-1 Receptor Antagonists; Phobic Disorders; Physical Conditioning, Animal; Piperidines; Psychopathology; Triazoles; Up-Regulation | 2011 |
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Polymorphism, Single Nucleotide; Triazoles | 2011 |
An accidental mass.
Topics: Accidents, Traffic; Adult; Aspergillus flavus; Caspofungin; Combined Modality Therapy; Coronary Thrombosis; Diagnosis, Differential; Disease Progression; Echinocandins; Echocardiography; Echocardiography, Transesophageal; Embolism; Emergency Service, Hospital; Endocarditis; Female; Fractures, Bone; Humans; Incidental Findings; Invasive Pulmonary Aspergillosis; Lipopeptides; Mediastinal Diseases; Pelvic Bones; Pyrimidines; Tomography, X-Ray Computed; Triazoles; Voriconazole | 2011 |
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Topics: Acetylation; Animals; Azepines; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatin; Disease Progression; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, myc; Histones; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Transcription Factors; Triazoles | 2011 |
Rhino-orbital-cerebral mucormycosis (ROCM): a comprehensive case review.
Topics: Adult; Amphotericin B; Antifungal Agents; Brain Diseases; Debridement; Diabetes Insipidus, Nephrogenic; Diabetes Mellitus, Type 1; Disease Progression; Eye Infections, Fungal; Humans; Immunocompromised Host; Magnetic Resonance Imaging; Male; Mucormycosis; Nose Diseases; Orbital Diseases; Tomography, X-Ray Computed; Triazoles | 2011 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Letrozole; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Nitriles; Positron-Emission Tomography; Radiopharmaceuticals; Spinal Neoplasms; Tomography, X-Ray Computed; Triazoles | 2010 |
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Nitriles; Osteoarthritis; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Effect of maraviroc on HIV disease progression-related biomarkers.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; Female; Fibrin Fibrinogen Degradation Products; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lipopolysaccharide Receptors; Lymphocyte Activation; Lymphocyte Count; Male; Maraviroc; Middle Aged; Receptors, CCR5; RNA, Viral; Triazoles; Viral Load | 2012 |
Ochroconis gallopavum infection in a lung transplant recipient: report of a case.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Biopsy; Bronchiolitis Obliterans; Disease Progression; Drug Administration Schedule; Enterobacter cloacae; Enterococcus; Fatal Outcome; Humans; Imipenem; Lung Transplantation; Male; Opportunistic Infections; Phaeohyphomycosis; Pyrimidines; Respiratory Tract Infections; Skin; Sputum; Tobramycin; Treatment Outcome; Triazoles; Voriconazole | 2012 |
Aromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Disease Progression; Endometriosis; Female; Laparoscopy; Letrozole; Menstruation; Nitriles; Organ Size; Ovary; Papio anubis; Peritoneum; RNA, Messenger; Treatment Outcome; Triazoles | 2013 |
Scedosporium apiospermum soft tissue infection as the initial presentation of acute myeloid leukemia: a case report.
Topics: Aged, 80 and over; Amputation, Surgical; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Humans; Leg Ulcer; Leukemia, Myeloid, Acute; Mycoses; Pancytopenia; Pyrimidines; Scedosporium; Soft Tissue Infections; Triazoles; Voriconazole | 2013 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2002 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Multicenter Studies as Topic; Nitriles; Reproducibility of Results; Research Design; Retrospective Studies; Survival; Tamoxifen; Triazoles | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Nitriles; Triazoles | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Nitriles; Triazoles | 2002 |
Unsuccessful treatment with voriconazole of a brain abscess due to Cladophialophora bantiana.
Topics: Aged; Antifungal Agents; Brain Abscess; Central Nervous System Fungal Infections; Cladosporium; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatal Outcome; Fungemia; Humans; Male; Pyrimidines; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Failure; Triazoles; Voriconazole | 2003 |
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Letrozole; Linear Models; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Ovariectomy; Tamoxifen; Transplantation, Heterologous; Triazoles; Uterus | 2004 |
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antifungal Agents; Brain; Colony Count, Microbial; Cryptococcosis; Cryptococcus neoformans; Disease Progression; Drug Therapy, Combination; Humans; Lung; Male; Mice; Survival Analysis; Triazoles | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Random Allocation; Tamoxifen; Time Factors; Triazoles | 2004 |
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Disease Progression; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Prognosis; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome; Triazoles | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Confidence Intervals; Disease Progression; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2005 |
Rare lower extremity invasive fungal infection in an immunosuppressed patient: Exserohilum longirostratum.
Topics: Aged; Antifungal Agents; Cellulitis; Comorbidity; Debridement; Disease Progression; Hepatitis C, Chronic; Humans; Immunocompromised Host; Leg Ulcer; Male; Mycoses; Pyrimidines; Triazoles; Voriconazole | 2006 |
Voriconazole therapeutic drug monitoring.
Topics: Adult; Aged; Antifungal Agents; Disease Progression; Drug Monitoring; Female; Humans; Male; Middle Aged; Pyrimidines; Retrospective Studies; Triazoles; Voriconazole | 2006 |
Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Endostatins; Female; Fibroblast Growth Factor 2; Humans; Letrozole; Male; Middle Aged; Nitriles; Predictive Value of Tests; Prospective Studies; Triazoles | 2006 |
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles; United States | 2006 |
Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
Topics: Atrophy; Benzoates; Biopsy; Brain; Ceruloplasmin; Chelation Therapy; Chorea; Deferasirox; Diagnosis, Differential; Disease Progression; Female; Ferritins; Gait Disorders, Neurologic; Humans; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Muscle Spasticity; Muscle, Skeletal; Neurodegenerative Diseases; Neurologic Examination; Neuropsychological Tests; Spleen; Triazoles | 2008 |
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Disease Progression; Enzyme Inhibitors; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Humans; Middle Aged; Tamoxifen; Time Factors; Treatment Failure; Treatment Outcome; Triazoles | 1999 |
False shortening of time to progression in letrozole 2.5-mg dose?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Nitriles; Triazoles | 2001 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Retrospective Studies; Treatment Failure; Triazoles | 2001 |